The U.N.-backed Medicines Patent Pool (MPP) said Thursday that 35 global firms have agreed to manufacture the generic version of Pfizer’s oral COVID-19 drug, Paxlovid, for distribution in 95 low-and middle-income countries. Paxlovid is a combination of two antiviral drugs–nirmatrelvir, which blocks the virus from replicating, and ritonavir–which slows down nirmatrelvir’s breakdown to help it…